Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Pre-Open Movers: Bed Bath & Beyond Sinks on Update, PayPal Gains on Upgrade

Published 08/31/2022, 09:16 AM
Updated 08/31/2022, 09:24 AM
© Reuters.  Pre-Open Movers: Bed Bath & Beyond Sinks on Update, PayPal Gains on Upgrade

© Reuters. Pre-Open Movers: Bed Bath & Beyond Sinks on Update, PayPal Gains on Upgrade

Pre-Open Stock Movers:

Bed Bath & Beyond Inc. (NASDAQ:BBBY) 24% LOWER; provides a strategic update, announcing job cuts, store closures, a 12 million share ATM offering, loan deal, and that it plans to keep buybuy BABY as part of the company.

Chewy (NYSE:CHWY) 10% LOWER; reported Q2 net income of $22.3 million. Revenue for the quarter came in at $2.43 billion versus the consensus estimate of $2.45 billion.

Ambarella (NASDAQ:AMBA) 10% LOWER; reported Q2 EPS of $0.20, $0.01 better than the analyst estimate of $0.19. Revenue for the quarter came in at $80.9 million versus the consensus estimate of $80.19 million. Ambarella sees Q3 2023 revenue of $81-85 million, versus the consensus of $85 million

Seagate Technology (NASDAQ:STX6% LOWER; now expects fiscal first quarter revenue of $2.1 billion plus or minus $100 million, which compares to the Company's previous guidance range of $2.5 billion plus or minus $150 million. The consensus is $2.52 billion.

Express Inc (NYSE:EXPR4% LOWER; reported Q2 EPS of $0.10, $0.01 better than the analyst estimate of $0.09. Revenue for the quarter came in at $464.9 million versus the consensus estimate of $479.62 million.

PVH Corp. (NYSE:PVH) 4% LOWER; reported Q2 EPS of $2.08, $0.08 better than the analyst estimate of $2.00. Revenue for the quarter came in at $2.13 billion versus the consensus estimate of $2.21 billion. PVH Corp. sees FY2022 EPS of $8.00, versus the consensus of $8.68.

HP Inc. (NYSE:HPQ) 4% LOWER; reported Q3 EPS of $1.04, in-line with the analyst estimate of $1.04. Revenue for the quarter came in at $14.7 billion versus the consensus estimate of $15.69 billion. HP Inc. sees Q4 2022 EPS of $0.79-$0.89, versus the consensus of $1.06. HP Inc. sees FY2022 EPS of $4.02-$4.12, versus the consensus of $4.30.

Rocket Lab USA, Inc. (NASDAQ:RKLB4% HIGHER; Cowen upgraded from Market Perform to Outperform with a price target of $8.00 (from $6.50).

Designer Brands Inc. (NYSE:DBI) 4% HIGHER; reported Q2 EPS of $0.62, $0.10 better than the analyst estimate of $0.52. Revenue for the quarter came in at $859.3 million versus the consensus estimate of $835.92 million. Designer Brands Inc. sees FY2022 EPS of $2.05-$2.15, versus the consensus of $1.89.

PayPal (NASDAQ:PYPL) 3% HIGHER; BofA Securities upgraded from Neutral to Buy with a price target of $114.00.

Western Digital Corporation (NASDAQ:WDC) 3% LOWER; Falls on Seagate's warning.

ChargePoint Holdings Inc (NYSE:CHPT2% HIGHER; reported Q2 EPS of ($0.19). Revenue for the quarter came in at $108 million versus the consensus estimate of $103.01 million. Chargepoint Holdings Inc. sees Q3 2023 revenue of $125-135 million, versus the consensus of $130 million. Chargepoint Holdings Inc. sees FY2023 revenue of $450-500 million, versus the consensus of $476.5 million.

Hewlett Packard Enterprise (NYSE:HPE) 1% HIGHER; reported Q3 EPS of $0.48, $0.01 better than the analyst estimate of $0.47. Revenue for the quarter came in at $7 billion versus the consensus estimate of $6.93 billion. Hewlett Packard Enterprise sees Q4 2022 EPS of $0.52-$0.60, versus the consensus of $0.58. Hewlett Packard Enterprise sees FY2022 EPS of $1.96-$2.04, versus the consensus of $2.03. Reiterates fiscal 2022 revenue growth of 3-4% adjusted for currency.

Amgen (NASDAQ:AMGN) 1% HIGHER; announced that the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS® (sotorasib) met its primary endpoint of progression-free survival (PFS), demonstrating statistical significance and superiority over standard of care chemotherapy, intravenous docetaxel. The first randomized clinical trial for a KRASG12C inhibitor assessed the efficacy and safety of LUMAKRAS in 345 previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) who had received at minimum, prior platinum-based doublet chemotherapy and checkpoint inhibitor therapy.

CrowdStrike Holdings Inc. (NASDAQ:CRWD) 1% LOWER; reported Q2 EPS of $0.36, $0.08 better than the analyst estimate of $0.28. Revenue for the quarter came in at $535.2 million versus the consensus estimate of $515.98 million. CrowdStrike Holdings Inc. sees Q3 2023 EPS of $0.30-$0.32, versus the consensus of $0.28. CrowdStrike Holdings Inc. sees Q3 2023 revenue of $569.1-575.9 million, versus the consensus of $568.6 million. CrowdStrike Holdings Inc. sees FY2023 EPS of $1.31-$1.33, versus the consensus of $1.20. CrowdStrike Holdings Inc. sees FY2023 revenue of $2.223-2.232 billion, versus the consensus of $2.2 billion.

Latest comments

All bullish
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.